Metrics as of 10/13/2026, 12:37 PM (Berlin time), refresh in progress.
Twist Bioscience Stock
Twist Bioscience Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Emily Marine Leproust
- Employees
- 979
- Market cap
- $9.4 B
- IPO
- 31/10/2018
Twist Bioscience Corporation operates as a leading synthetic biology firm specializing in the biotechnology industry. Founded in 2013, the company is headquartered in South San Francisco, USA. The business model focuses on the production and sale of products developed from synthesized DNA. The corporation utilizes a…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Twist Bioscience stock: price history
1D
-0.3%
1W
-9.4%
1M
+19.0%
6M
+163.6%
YTD
+377.1%
1Y
+402.1%
2Y
+240.3%
5Y
+53.6%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~52% stronger price swings than usual
Twist Bioscience stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
3 more assignments (Enabler/Second row) Pro-only.
Twist Bioscience is a leading company in synthetic biology specializing in the manufacturing and sale of synthetic DNA-based products. The core technology is based on a unique DNA synthesis platform on silicon chips. The product portfolio includes custom synthetic genes, sample preparation tools, and antibody libraries for pharmaceutical research and development. Additionally, the company is researching applications for digital data storage using DNA. Business operations are primarily based on the sale of specialty products and research reagents to pharmaceutical and biotech companies, complemented by strategic partnerships and alliances to further develop sequencing technologies and therapeutic antibodies.
- Revenue model
- Hardware sales
- Recurring revenue
- Low
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Twist Bioscience
Analyst assessment of Twist Bioscience
PRICE TARGET LOW
US$89.00
CONSENSUS
US$153.70
MEDIAN
US$147.00
PRICE TARGET HIGH
US$215.00
0
STRONG BUY
11
BUY
2
HOLD
2
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 13/10/2026
Twist Bioscience stock metrics
P/E
-68.17
P/B
21.19
EV/EBITDA
-87.2
RETURN ON EQUITY
-7.9%
NET MARGIN
-29.6%
DEBT/EQUITY
0.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.9%
FLOAT SHARES
59,694,264
AVG. DAILY VOLUME (30D)
2,671,932
Insider transactions (SEC)
Laponis Adam
Leproust Emily M.
Leproust Emily M.
Leproust Emily M.
Leproust Emily M.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.3%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Twist Bioscience stock
What does Twist Bioscience do?
Twist Bioscience Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Emily Marine Leproust, the company employs around 979 people.
The IPO was on 31/10/2018; the stock trades on NASDAQ under the ticker TWST.
What do analysts say about Twist Bioscience stock?
15 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$153.70, ranging from US$89.00 to US$215.00, with a median of US$147.00.
This is an external assessment, not a statement by Market Jury.
When does Twist Bioscience report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 52% stronger than usual.
Does Twist Bioscience pay a dividend?
No, Twist Bioscience currently does not pay a dividend.
Which stocks are comparable to Twist Bioscience?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Twist Bioscience stock analyzed?
Clicking "Analyze stock" lets five strategies assess Twist Bioscience against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.